Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Army
Harvard Business School
Healthtrust
Chinese Patent Office
Daiichi Sankyo
Teva
Dow
QuintilesIMS

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203928

« Back to Dashboard

NDA 203928 describes POLYETHYLENE GLYCOL 3350, which is a drug marketed by Ani Pharms Inc, Apnar Pharma Lp, Aurobindo Pharma Ltd, Breckenridge Pharm, Mylan, Nexgen Pharma, Nexgen Pharma Inc, Novel Labs Inc, Nuvo Pharm Inc, Paddock Llc, Par Pharm, Perrigo R And D, Strides Pharma, and Teva Pharms, and is included in sixteen NDAs. It is available from sixty-nine suppliers. Additional details are available on the POLYETHYLENE GLYCOL 3350 profile page.

The generic ingredient in POLYETHYLENE GLYCOL 3350 is polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous. There are four hundred and nineteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous profile page.
Summary for 203928
Tradename:POLYETHYLENE GLYCOL 3350
Applicant:Strides Pharma
Ingredient:polyethylene glycol 3350
Patents:0
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 203928
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
POLYETHYLENE GLYCOL 3350 polyethylene glycol 3350 FOR SOLUTION;ORAL 203928 ANDA Strides Pharma Inc 59556-762 N 59556-762-01
POLYETHYLENE GLYCOL 3350 polyethylene glycol 3350 FOR SOLUTION;ORAL 203928 ANDA Strides Pharma Inc 59556-762 N 59556-762-02

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:FOR SOLUTION;ORALStrength17GM/SCOOPFUL
Approval Date:Aug 24, 2016TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:OTCDosage:FOR SOLUTION;ORALStrength17GM/PACKET
Approval Date:Aug 24, 2016TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Fish and Richardson
Moodys
Dow
Citi
Fuji
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.